Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

被引：0
作者：
Mathilde Bureau
Thierry Chatellier
Tanguy Perennec
Thomas Goronflot
Charlotte Greilsamer
Anne-Laure Chene
Raafet Affi
Eric Frampas
Jaafar Bennouna
Elvire Pons-Tostivint
机构：
[1] University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de Nantes
[2] Medical Oncology Unit,Department of Radiation Oncology
[3] Institut de Cancerologie de L’Ouest,INSERM
[4] University Hospital of Nantes,Pneumology Unit
[5] Medical Oncology Unit,Radiology Unit
[6] University Hospital of Nantes,undefined
[7] University Hospital of Nantes,undefined
[8] INSERM,undefined
[9] CRCINA,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Baseline tumour size; Non-small cell lung cancer; Immune checkpoint inhibitor; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1747 / 1756
页数：9
相关论文
共 50 条
  • [31] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
    Kawachi, Hayato
    Tamiya, Motohiro
    Tamiya, Akihiro
    Ishii, Seigo
    Hirano, Katsuya
    Matsumoto, Hirotaka
    Fukuda, Yasushi
    Yokoyama, Toshihide
    Kominami, Ryota
    Fujimoto, Daichi
    Hosoya, Kazutaka
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Kanazu, Masaki
    Sawa, Nobuhiko
    Uchida, Junji
    Morita, Mitsunori
    Makio, Takeshi
    Hara, Satoshi
    Kumagai, Toru
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 211 - 218
  • [32] Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?
    Bozkaya, Yakup
    Kostek, Osman
    Sakin, Abdullah
    Ozyukseler, Deniz Tataroglu
    Sakalar, Teoman
    Cil, Ibrahim
    [J]. SUPPORTIVE CARE IN CANCER, 2020, 28 (05) : 2273 - 2282
  • [33] Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?
    Yakup Bozkaya
    Osman Köstek
    Abdullah Sakin
    Deniz Tataroğlu Özyükseler
    Teoman Şakalar
    İbrahim Çil
    [J]. Supportive Care in Cancer, 2020, 28 : 2273 - 2282
  • [34] Cost-effectiveness analysis of PD-L1 testing associated with pembrolizumab for first-line treatment of advanced non-small cell lung cancer in China
    Wu, Yao
    Tao, Libo
    Liu, Chang
    Wang, Fangxu
    Sun, Shuang
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2025, : 737 - 746
  • [35] Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab
    Florian Eude
    Florian Guisier
    Mathieu Salaün
    Luc Thiberville
    Thibault Pressat-Laffouilhere
    Pierre Vera
    Pierre Decazes
    [J]. Annals of Nuclear Medicine, 2022, 36 : 224 - 234
  • [36] Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
    Vrankar, Martina
    Kern, Izidor
    Stanic, Karmen
    [J]. RADIATION ONCOLOGY, 2020, 15 (01)
  • [37] Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab
    Eude, Florian
    Guisier, Florian
    Salaun, Mathieu
    Thiberville, Luc
    Pressat-Laffouilhere, Thibault
    Vera, Pierre
    Decazes, Pierre
    [J]. ANNALS OF NUCLEAR MEDICINE, 2022, 36 (03) : 224 - 234
  • [38] Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies
    Shukuya, Takehito
    Mori, Keita
    Amann, Joseph M.
    Bertino, Erin M.
    Otterson, Gregory A.
    Shields, Peter G.
    Morita, Satoshi
    Carbone, David P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : 1927 - 1939
  • [39] Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%
    Metro, Giulio
    Banna, Giuseppe Luigi
    Signorelli, Diego
    Gili, Alessio
    Galetta, Domenico
    Galli, Giulia
    Economopoulou, Panagiota
    Roila, Fausto
    Friedlaender, Alex
    Camerini, Andrea
    Christopoulou, Athina
    Cantale, Ornella
    De Toma, Alessandro
    Pizzutilo, Pamela
    Jimenez, Beatriz
    Collazo-Lorduy, Ana
    Calles, Antonio
    Baxevanos, Panagiotis
    Linardou, Helena
    Kosmidis, Paris
    Giannarelli, Diana
    Mountzios, Giannis
    Addeo, Alfredo
    [J]. JOURNAL OF IMMUNOTHERAPY, 2020, 43 (09) : 299 - 306
  • [40] First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis
    Mingfeng He
    Taihao Zheng
    Xiaoyue Zhang
    Yuan Peng
    Xuan Jiang
    Yusheng Huang
    Benxu Tan
    Zhenzhou Yang
    [J]. Cancer Immunology, Immunotherapy, 2022, 71 : 1345 - 1355
12345